Valuation: Gilead Sciences, Inc.

Market Cap 165B 247,596B 143B 133B 122B 230B 15,720B 234B 1,565B 614B 7,879B 620B 607B 26,048B P/E 2026 *
-41.4x
P/E 2027 * 16.7x
Enterprise Value 182B 272,698B 157B 147B 135B 254B 17,314B 258B 1,724B 677B 8,678B 683B 668B 28,689B EV / Sales 2026 *
5.93x
EV / Sales 2027 * 5.33x
Free-Float
99.87%
Yield 2026 *
2.47%
Yield 2027 * 2.56%
1 day+2.62%
1 week+2.72%
Current month+2.72%
1 month-1.17%
3 months+8.34%
6 months-5.75%
Current year+12.73%
1 week 50,825
Extreme 50825
53,925
1 month 50,500
Extreme 50500
55,075
Current year 44,320
Extreme 44320
58,100
1 year 36,450
Extreme 36450
58,100
3 years 11,795
Extreme 11795
58,100
5 years 2,682.5
Extreme 2682.5
58,100
10 years 656.5
Extreme 656.5
58,100
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.62%+2.72% - - 165B
-0.52%+3.21%+89.52%+125.32% 1,057B
+0.88%+1.13%+49.56%+49.79% 625B
+0.89%-1.95%+24.23%+63.19% 435B
+0.97%+4.02%+50.35%+38.74% 363B
+0.26%+1.29%+31.33%+39.21% 296B
+0.36%+3.67%+8.03%+6.81% 249B
+1.51%+6.69%+42.58%+58.47% 222B
-0.49%+0.22%-6.09%-51.45% 209B
+1.80%+2.30%+11.56%+66.16% 165B
Average +0.26%+0.94%+33.45%+44.03% 402.31B
Weighted average by Cap. +0.26%+1.33%+48.54%+63.96%

Financials

2026 *2027 *
Net sales 30.68B 45,986B 26.54B 24.78B 22.73B 42.76B 2,920B 43.44B 291B 114B 1,463B 115B 113B 4,838B 32.67B 48,978B 28.26B 26.39B 24.21B 45.54B 3,110B 46.26B 310B 122B 1,559B 123B 120B 5,153B
Net income -4.16B -6,243B -3.6B -3.36B -3.09B -5.8B -396B -5.9B -39.47B -15.49B -199B -15.64B -15.3B -657B 10.21B 15,304B 8.83B 8.25B 7.57B 14.23B 972B 14.46B 96.76B 37.98B 487B 38.34B 37.5B 1,610B
Net Debt 16.75B 25,101B 14.48B 13.53B 12.41B 23.34B 1,594B 23.71B 159B 62.29B 799B 62.88B 61.51B 2,641B 9.12B 13,678B 7.89B 7.37B 6.76B 12.72B 868B 12.92B 86.48B 33.94B 435B 34.26B 33.51B 1,439B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
07/08/26 ARS 52,825.00 +2.62% 1,251
06/08/26 ARS 51,475.00 -0.91% 2,849
05/08/26 ARS 51,950.00 -2.17% 972
04/08/26 ARS 53,100.00 +3.01% 1,575
03/08/26 ARS 51,550.00 +0.24% 419
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
133.21USD
Average target price
157.41USD
Spread / Average Target
+18.16%

Quarterly revenue - Rate of surprise